Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cytarabine/daunorubicin - Jazz Pharmaceuticals

Drug Profile

Cytarabine/daunorubicin - Jazz Pharmaceuticals

Alternative Names: CPX-351; Cytarabine/daunorubicin liposomal; Cytarabine:daunorubicin - Jazz Pharmaceuticals; Cytarabine:daunorubicin liposome injection - Jazz Pharmaceuticals; Daunorubicin/cytarabine; Liposomal AraC-Daunorubicin CPX-351; NS 87; VYXEOS; Vyxeos

Latest Information Update: 25 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celator Pharmaceuticals
  • Developer Cardiff University; Celator Pharmaceuticals; Children's Oncology Group; Cincinnati Childrens Hospital Medical Center; Fred Hutchinson Cancer Research Center; Jazz Pharmaceuticals plc; National Cancer Institute (USA); Stanford University; The Leukemia & Lymphoma Society; University of Texas M. D. Anderson Cancer Center; University of Washington
  • Class Anthracyclines; Antineoplastics; Arabinonucleosides; Cytostatic antibiotics; Daunorubicins; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA intercalators; DNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase III Myelodysplastic syndromes
  • Phase II Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Lymphoma

Most Recent Events

  • 15 Oct 2019 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, First-line therapy) in USA (IV) (NCT04038437)
  • 02 Sep 2019 Jazz Pharmaceuticals plans the phase Ib V-FAST trial for Acute myeloid leukaemia (Combination therapy, First-line therapy, Newly diagnosed) in October 2019 (NCT04075747)
  • 12 Aug 2019 Nippon Shinyaku plans a phase I/II trial for Acute myeloid leukaemia (second-line therapy or greater) in Japan (Nippon Shinyaku pipeline August 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top